Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 25

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 — — — (208)— (208)Dividends declared— — — — (5,507)— — (5,507)Purchases of treasury stock(7)— (1,333)— — — — (1,333)Stock-based compensation plans and other7 — 28 699 — — — 727 Change in noncontrolling interest— — — — — — 6 6 Balance at June 30, 20241,766 $18 $(7,838)$20,879 $(3,768)$(2,513)$43 $6,821 Balance at December 31, 20241,765 $18 $(8,201)$21,333 $(7,900)$(1,925)$39 $3,364 Net earnings attributable to AbbVie Inc.— — — — 2,224 — — 2,224 Other comprehensive income, net of tax— — — — — 387 — 387 Dividends declared— — — — (5,827)— — (5,827)Purchases of treasury stock(5)— (973)— — — — (973)Stock-based compensation plans and other6 — 27 654 — — — 681 Change in noncontrolling interest— — — — — — 6 6 Balance at June 30, 20251,766 $18 $(9,147)$21,987 $(11,503)$(1,538)$45 $(138)

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 4

AbbVie Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (unaudited) 

Six months endedJune 30,(in millions) (brackets denote cash outflows)20252024Cash flows from operating activitiesNet earnings$2,230 $2,745 Adjustments to reconcile net earnings to net cash from operating activities:Depreciation367 367 Amortization of intangible assets3,722 3,838 Deferred income taxes(300)(405)Change in fair value